Centaurus Financial Inc. decreases position in Johnson & Johnson (NYSE:JNJ)

VaselineOctober 4, 2024

0 4 minutes read

Centaurus Financial Inc. cut its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 12.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,689 shares of the company’s stock after selling 1,186 shares during the period. The holdings of Centaurus Financial Inc. in Johnson & Johnson were worth $1,270,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have added to or reduced their stakes in the company. Inçalta Capital LLC purchased a new stake in shares of Johnson & Johnson in the second quarter valued at about $27,000. MFA Wealth Advisors LLC purchased a new stake in shares of Johnson & Johnson in the second quarter valued at about $43,000. Vermillion & White Wealth Management Group LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $44,000. Fairfield Financial Advisors LTD purchased a new stake in shares of Johnson & Johnson in the second quarter valued at about $46,000. Finally, Grayhawk Investment Strategies Inc. boosted its holdings in shares of Johnson & Johnson by 528.6% in the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock worth $48,000 after purchasing an additional 259 shares during the period. 69.55% of the shares are currently held by hedge funds and other institutional investors.

Changes in Analyst Ratings

Several equities research analysts recently weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Monday. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Daiwa Capital Markets downgraded Johnson & Johnson from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $160.00 to $150.00 in a report on Tuesday, the 23rd July. Morgan Stanley boosted their price objective on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a report on Thursday, July 18th. Finally, TD Cowen decreased their price target on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, July 18th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $173.21, based on data from MarketBeat.

Want more great investment ideas?

Read the latest stock report on JNJ

Insider buying and selling

In related news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible via this hyperlink. 0.16% of shares are currently owned by company insiders.

Johnson & Johnson shares fell 0.4%

Shares of Johnson & Johnson stock opened at $160.50 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07, and a quick ratio of 0.85. The stock has a market cap of $386.27 billion, a price-to-earnings ratio of 10.01, a PEG ratio of 2.69 and a beta of 0.53. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The company has a fifty day moving average price of $162.61 and a 200 day moving average price of $154.30.

Johnson & Johnson (NYSE:JNJ – Get Your Free Report ) last issued its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The company had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company’s quarterly revenue was up 4.3% year over year. In the same quarter last year, the business posted EPS of $2.80. equities research analysts forecast that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson announces dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were given a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, August 27th. This represents a dividend of $4.96 on an annualized basis and a yield of 3.09%. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Johnson & Johnson profile

(Free report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures and sells various health products worldwide. The company’s Innovative Medicines segment offers products for various therapeutic areas such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis; infectious diseases including HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders and schizophrenia; oncology, such as prostate cancer, hematological malignancies, lung cancer and bladder cancer; cardiovascular and metabolic, including thrombosis, diabetes and macular degeneration; and pulmonary hypertension including pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use.